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Abstract
Background: The development of cell-based therapeutics for humans requires preclinical testing
in animal models. The use of autologous animal products fails to address the efficacy of similar
products derived from humans. We used a novel immunodeficient rat carotid injury model in order
to determine whether human cells could improve vascular remodelling following acute injury.
Methods:  Human CD34+ cells were separated from peripheral buffy coats using automatic
magnetic cell separation. Carotid arterial injury was performed in male Sprague-Dawley nude rats
using a 2F Fogarty balloon catheter. Freshly harvested CD34+ cells or saline alone was
administered locally for 20 minutes by endoluminal instillation. Structural and functional analysis of
the arteries was performed 28 days later.
Results: Morphometric analysis demonstrated that human CD34+ cell delivery was associated
with a significant reduction in intimal formation 4 weeks following balloon injury as compared with
saline (I/M ratio 0.79 ± 0.18, and 1.71 ± 0.18 for CD34, and saline-treated vessels, respectively P <
0.05). Vasoreactivity studies showed that maximal relaxation of vessel rings from human CD34+
treated animals was significantly enhanced compared with saline-treated counterparts (74.1 ± 10.2,
and 36.8 ± 12.1% relaxation for CD34+ cells and saline, respectively, P < 0.05)
Conclusion: Delivery of human CD34+ cells limits neointima formation and improves arterial
reactivity after vascular injury. These studies advance the concept of cell delivery to effect vascular
remodeling toward a potential human cellular product.
Background
Cellular therapies hold great promise for the treatment of
human disease. The development of cell-based therapeu-
tics for humans requires preclinical testing in animal
models. There are inherent limitations to the use of autol-
ogous animal products for preclinical testing. First, the use
of autologous animal products fails to address the specific
efficacy of the intended human product. Second, immu-
nophenotyping of animal products may be limited by a
lack of reagents which are available for use in humans and
thus fail to predicate human results. To overcome these
limitations and in order to develop novel human cellular
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products, immunodeficient animals may be used to test
the delivery of these products.
We and others have demonstrated the vasculoprotective
effects of local delivery of circulation and adipose-derived
cells with an endothelial phenotype following acute vas-
cular injury [1-4]. These effects include a reduction in
neointimal formation and improvement in vascular reac-
tivity. These studies suggest that cell delivery may improve
large vessel healing which might be extrapolated to clini-
cal scenarios such as post-angioplasty or stenting. How-
ever, the translational potential of these studies has been
hindered by two important issues. First, the cells have
been cultured under variable conditions prior to delivery
[1,2]. Second, rabbit-specific reagents that define circulat-
ing precursors are limited. Thus, identification of a circu-
lating cell capable of these vasoprotective effects would be
an advance.
CD34 is a hematopoietic progenitor cell marker. In a
landmark publication by Asahara in 1997, bone marrow
derived cells expressing CD34 were demonstrated to dif-
ferentiate ex vivo to an endothelial phenotype [5]. The
function of CD34 is uncertain, but it is thought to be a cell
to cell adhesion molecule that anchors hematopoeitic
progenitor cells to the bone marrow stroma and also facil-
itates their interaction with other stromal cells. Interest-
ingly, it is also known that there is a complex interaction
between bone marrow derived progenitor cells (hemato-
poetic progenitor cells, HPCs) and microvascular
endothelial cells in bone marrow. Endothelial cells appear
to regulate the trafficking and release of HPCs from bone
marrow [6]. CD34 is also expressed on microvascular
endothelial cells, and this shared antigen expression
between microvascular endothelium and hematopoietic
progenitors is also strongly supportive of a shared embry-
ological origin and that hematopoiesis and vasculogene-
sis are linked in the embryo. The ability of circulating
CD34+ cells to adapt an endothelial phenotype is well
established [5]. As such, we aimed to test the hypothesis
that delivery of human CD34+ cells would be vasculopro-
tective. To do so, we developed a model of acute carotid
artery injury in an immunodeficient rat model.
Methods
Isolation and selection of human CD34+ cells from 
peripheral blood
Leukocyte filter eluates (10 mls) of human whole blood
were obtained from normal donors after leukophaeresis
[7]. Human whole blood samples were obtained from
healthy volunteers after approval from the Mayo Clinic
Institutional Review Board Approval. The cells were incu-
bated with anti-CD34-conjugated superparamagnetic
microbeads (CD34 Isolation kit; Miltenyi Biotec),
washed, and processed to obtain purified CD34 cells.
FACS was also performed on freshly immunoselected
CD34 cells to determine their phenotypic profile and
purity.
Flow cytometry
Purified cells were counted and re-suspended in seven 100
μL aliquots of PBS for FACS analysis, each containing
approximately 105  cells. After addition of Fc receptor
blocking antibody (Miltenyi Biotec) to each tube, cells
were incubated with fluorochrome-conjugated antibodies
to CD34 (FITC), CD45 (PerCP) (both from BD bio-
sciences), CD133 (PE) (Miltenyi Biotec), and VEGFR2
(APC) (R&D Systems). Murine IgG1 (R&D Systems) con-
jugated to Alexa 488, PE (Molecular Probes), and Rat anti-
mouse PerCP (BD Biosciences) was used as isotype con-
trols as well as IgG1-APC from BD Biosciences.
Carotid injury model in immunodeficient rats
All animal procedures were approved by the Mayo Clinic
Institutional Animal Care and Use Committee. Immuno-
deficient rats (Sprague-Dawley) were housed at constant
room temperature (24 ± 1°C) and humidity (60 ± 3%).
The athymic nude mutant rat (Hsd:RH-Foxn1^rnu) repre-
sents a well-established research model that has already
made a substantial contribution to many scientific disci-
plines, such as immunology and cancer research. The rnu
allele on chromosome 10 is an autosomal recessive muta-
tion associated with hairlessness and thymic aplasia. The
thymus-dependent lymph node areas are depleted of lym-
phocytes (T-cells). The animals are phenotypically hair-
less and have rudimentary thymic tissue present. Male e
rats (3 to 4 months old weighing 350 to 400 g) were anes-
thetized with an intramuscular injection of ketamine 50
mg/kg, xylazine 10 mg/kg, and acepromazine 1 mg/kg.
Under general anaesthesia and by using an operating
microscope, a midline incision was made in the neck to
expose the left external carotid artery. A 2F Fogarty bal-
loon embolectomy catheter (Baxter) was introduced into
the left external carotid artery and advanced through the
common carotid artery to the aortic arch. The balloon was
inflated with saline (0.02 ml) until a slight resistance was
felt and then was rotated while pulling it back through the
common carotid artery to denude the vessel of endothe-
lium. This procedure was repeated two more times (total
of three passes), and then the catheter was removed.
Immediately after catheter withdrawal, residual material
was removed and 200 μl of saline with freshly selected
CD34+ cells and saline alone was administered locally by
intra-vascular instillation for 20 minutes through a 24G
catheter. The external carotid was ligated with a 6-0 silk
suture and the blood flow restored by removing the clips
at the common and internal carotid arteries. After inspec-
tion to ascertain adequate pulsation of the common
carotid artery, the surgical incision was closed, and the rats
were allowed to recover from anaesthesia in a humidifiedJournal of Translational Medicine 2009, 7:66 http://www.translational-medicine.com/content/7/1/66
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and warmed chamber for 2 to 4 hours. The animals were
euthanized with an overdose of pentobarbital (200 mg/
kg) 28 days after balloon injury, and the carotid arteries
were collected for molecular, mechanical, and histological
analyses.
Cell tracking Studies
In order to track the fate of delivered cells, human CD34+
cells were labelled with CM-DiI (1 μg/ml), a fluorescent
membrane dye (Molecular Probes), and resuspended in
200  μl saline for subsequent administration. Animals
were euthanized after 4 weeks with an overdose of pento-
barbital sodium. Both carotids were excised, embedded in
OCT (Tissue-Tek), and immersed in 2-methylbutane
cooled by liquid nitrogen. Mounted 5 μm sections were
examined under fluorescence microscopy for detection of
CM-DiI-labeled cells.
Effects of cell delivery on vascular form and function
Immunodeficient rats were assigned to 3 groups (n = 8 per
group) to determine vasoreactivity and development of
neointima formation at 4 weeks after balloon injury.
Group 1 rats received no balloon injury and served as
uninjured controls. Group 2 rats underwent balloon cath-
eter injury to the left common carotid artery, received
human CD34 cells as defined above, and were sacrificed
at 4 weeks after balloon injury. Group 3 rats underwent
balloon catheter injury to the left common carotid artery,
received normal saline, and were sacrificed at 4 weeks
after balloon injury.
Arterial vasoreactivity
Four weeks after balloon injury and local CD34+ cells or
saline delivery, animals were euthanized and carotids
immediately immersed in cold Krebs solution. Arterial
rings ~3 mm in length (3 per artery) were carefully dis-
sected from the surrounding adipose tissue under a micro-
scope with great care taken to protect the endothelium.
The carotid rings were then connected to isometric force
displacement transducers and suspended in organ cham-
bers filled with 25 ml of Krebs (94% O2, 6% CO2) solu-
tion. Rings were equilibrated for 1 hour at 37°C and then
incrementally stretched to 2 g. Viability and maximum
contraction was determined with 60 mM KCl. After 3
washes with Krebs solution and further equilibration,
arteries were precontracted with phenylephrine in a
titrated fashion to achieve ~80% stable maximal contrac-
tion. To study endothelium dependent relaxation, acetyl-
choline (10-9 to 10-5 M) was added to the organ bath in a
cumulative manner. Following 3 further washes and equi-
libration, the arteries were recontracted, and viability was
confirmed by assessment of endothelium independent
responses to sodium nitroprusside, an exogenous NO
donor.
Morphometric analysis
The carotid arteries were perfusion-fixed at a constant
physiological pressure of 125 mm Hg with 4% parafor-
maldehyde. The carotid arteries were carefully stripped of
adventitia and excised between the origin at the aorta and
the carotid bifurcation. The proximal segment (0.3 cm) of
the denuded arteries was removed and fixed in 4% para-
formaldehyde for 12 hours before being embedded in
paraffin and used for morphometric analysis. The cross
sections (5 μm) of carotid artery were generated at 200 μm
intervals, paired slides being then stained with LELVG or
H&E for morphometric analysis. The first three slides (400
μm apart) were analyzed to define the effects on neointi-
mal formation. Endoluminal, internal elastic laminar and
external elastic laminar borders were manually traced,
digitally measured, and analyzed using software (Image
ProPlus) to calculate intimal and medial areas. Because
native media thickness is variable (reflecting the diameter
of the artery), it was used to index the area of neointima
resulting from balloon injury. Accordingly, neointimal
thickness was assessed in terms of intima to media area
ratios.
Statistical analysis
Vasoreactivity data were analyzed with ANOVA for
repeated measures; direct pair wise comparisons between
groups were made with Scheffe's t-test. Intima/Media
ratios were compared with unpaired t-tests. A value of P <
0.05 was considered to be statistically significant. Data are
presented as mean ± SEM.
Results and discussion
Isolation and characterization of human CD34+ cells
Human CD34+ cells (1 to 3 × 106 CD34+ cells) were
obtained from normal human donors using two sequen-
tial positive magnetic automated cell separations (MACS)
immediately upon receipt of blood sample. Freshly iso-
lated CD34+ cells from blood (purity 87 ± 13%) uni-
formly expressed CD45dim  while 61 ± 9% of cells
expressed CD133 and less than 1% of CD34+ cells were
positive for VEGFR2 (Figure 1).
Tracking of delivered human CD34+ cells
To determine whether delivery of cells resulted in any cell
retention for the 4 weeks following delivery, carotid sec-
tions were examined under fluorescence microscopy for
detection of CM-DiI-labeled cells. Specific red fluores-
cence identified the presence of labeled human CD34+
cells within the neointima, media, and adventitia of
injured segments. No labeled cells were identified in
uninjured control arteries. In animals receiving human
CD34+ cells, only 12.5% of carotid sections demonstrated
fluorescent luminal endothelial cells at 4 weeks. Labeled
cells were seen in the media (Figure 2) but also in theJournal of Translational Medicine 2009, 7:66 http://www.translational-medicine.com/content/7/1/66
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neointima and adventitia under fluorescent microscopy.
This finding is very consistent with previous findings in
circulation-derived cells [1] and suggests a paracrine
mechanism for these effects.
Vasculoprotective effects of peripheral human CD34+ cells
Four weeks after balloon injury and local delivery of
CD34+ cells or saline, animals were euthanized and carot-
ids immediately immersed in cold Krebs solution. Follow-
ing pre-contraction with phenylephrine in an organ
chamber, relaxation in response to incremental doses of
acetylcholine was assessed (Figure 3). Maximal relaxation
of vessel rings from human CD34+ treated animals was
significantly enhanced compared with saline-treated
counterparts (74.1 ± 10.2 and 36.8 ± 12.1% relaxation for
CD34+ cells and saline, respectively, P < 0.05 for CD34+
cells vs. saline). The concentration (-Log M) of acetylcho-
line required to achieve 25% of maximal relaxation
(EC25) was 7.19 ± 0.04 in CD34 treated animals com-
pared with 5.38 ± 0.06 in saline treated animals (p <
0.005). Although the data clearly demonstrates that
CD34+ cell delivery enhanced endothelium dependent
vasorelaxation, responses did not achieve those of unin-
jured vessels which retained the largest responses to ace-
tylcholine (p < 0.05 for maximal relaxation and EC50
compared with CD34 treatment).
Morphometric analysis demonstrated that human CD34+
cell delivery was associated with a significant reduction in
neointimal formation 4 weeks following balloon injury as
compared with saline. Intima-to-media ratios were 0.79 ±
0.18, and 1.71 ± 0.18 for CD34, and saline-treated vessels,
Characterization of human CD34+ cells Figure 1
Characterization of human CD34+ cells. A. Scatter analysis reveals a low side scatter and low to intermediate forward 
scatter population in keeping with small round cells, as shown in (B) photomicrograph (200×). C. FACS analysis of isolated 
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respectively (P < 0.05 for CD34 vs. saline treated vessels)
(Figure 4). This suggests that, in addition to improving
endothelium-dependent relaxation, local delivery of
CD34+ cells also attenuated neointimal formation after
arterial injury in this immunodeficient rat model.
Why CD34 + cells?
Endothelial progenitor cells (EPCs) are the most studied
vascular progenitors [8]. New understandings of the
inherent role of circulating cells, including precursor cells,
in postnatal neovascularization have presented novel
therapeutic opportunities. Studied applications of
endothelial-lineage cell therapy have demonstrated
enhancement of new capillary formation in ischemic tis-
sue (therapeutic vasculogenesis) and generation of an
anti-thrombogenic luminal surfaces in prosthetic grafts
[9-13].
Tracking of delivered cells Figure 2
Tracking of delivered cells. Light microscopy cross sec-
tion (20×) showing neointima formation in immunodeficient 
rat carotid 4 weeks after balloon injury (A). CM-Dil-labeled 
human CD34+ cells stain red under fluorescent microscope 
(20×) within intima and media of carotid 4 weeks after bal-
loon injury (B). IEL = Internal elastic lamina, EEL = external 
elastic lamina.
Cell delivery improves vasoreactivity Figure 3
Cell delivery improves vasoreactivity. Human CD34+ 
cell delivery improves endothelium-dependent vasoreactivity 
after arterial injury. Carotid rings from CD34+ cell treated 
rats (open squares) show markedly enhanced vasoreactivity 
to acetylcholine 4 weeks after injury compared to saline con-
trols (diamonds)(P < 0.05 for CD34+ cells vs. saline). How-
ever, uninjured left carotid arteries retained the largest 
relaxation responses (P < 0.05, vs. CD34+ treated rings). Val-
ues are means ± SE. n = 8/group.











































Cell delivery reduces neointimal formation Figure 4
Cell delivery reduces neointimal formation. Local 
delivery of human CD34+ cells reduces neointimal formation 
after balloon injury. Significant attenuation of intima-to-media 
ratio in CD34+ treated vessels compared with saline treated 
control groups 4 weeks after injury (P < 0.05 for CD34+ 
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The current study tested whether specifically selected fresh
human CD34+ cells without culture modification may
have an applied role in modulating the vascular response
to balloon injury. Unfortunately, no single definition of
vascular progenitor cells exists, and it is unknown which
is the best antigenic profile to identify progenitor cells
linked to vascular and endothelial disease. Additionally, it
is unclear as to what defines the best cells for vasculopro-
tective delivery. Performance of these studies necessitated
the use of human reagents and an immunodeficient
model. Therefore, this current study using freshly derived
cells of surface antigens, represents a valid alternative of
cellular therapy for vascular disease being time-saving,
inexpensive, precise, and reproducible. Also, this reagent
has been used extensively in humans for transplantation
with an excellent safety profile.
The finding of delivered cells over a small proportion of
the luminal surface suggests direct but incomplete partic-
ipation of CD34+ cells in endothelial re-surfacing.
Although the proportion may have been underestimated
due to loss of fluorescence with cell division, it should not
have been to such an extent as seen in our study. Thus,
indirect mechanisms may also be involved. CD34+ cell
incorporation may alter the kinetics of the denuded sur-
face to induce proliferation of neighboring resident
endothelium or recruit additional circulating precursors.
In support of this possibility, it has been shown that BM-
endothelial lineage cells express angiogenic ligands and
cytokines [14,15] and induce proliferation of preexisting
vasculature in the vicinity of myocardial infarcts [16].
The margin by which CD34+ cell delivery improved
endothelial-dependent vasoreactivity is an important fea-
ture of this study. The effect is likely to be mediated at
least in part by accelerated re-endothelialization. How-
ever, non-luminally located cells (as were also found in
this study) could additionally influence vascular reactivity
through paracrine mechanisms including the release of
nitric oxide (NO) into the surrounding milieu. Indeed,
adenoviral gene transfer of eNOS to the adventitia has
been shown to improve NO production and vasoreactiv-
ity even in arteries without endothelium [17]. The benefit
conferred by CD34+ cell delivery was seen after 28 days. It
is also compatible with a paracrine hypothesis as outlined
above, but the relative contribution of direct and indirect
cell effects remain to be determined.
Conclusion
The vasoprotective effects of freshly isolated human
CD34+ cells without in vitro manipulation have been
demonstrated in this novel animal model of carotid
injury. Improvement in arterial vasoreactivity and
decrease in neointima formation was observed in con-
junction with delivery of selected CD34+ cells. This pre-
clinical model has important implications for transla-
tional studies to clinical medicine.
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